September 15th 2023
The FDA has approved momelotinib (Ojjaara) for the treatment of adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, and anemia.
July 2nd 2023
Jaktinib is a novel JAK and AVCR1 inhibitor that showed activity in patients with myelofibrosis who were intolerant to or progressed on ruxolitinib.
June 29th 2023
For patients with myelofibrosis receiving pacritinib, spleen volume reduction was associated with improved overall survival.
April 27th 2023
Specialists highlight the best practices and latest treatment regimens for patients presenting with myelofibrosis, polycythemia vera, and essential thrombocythemia.
March 9th 2023
After 6 months of treatment with ruxolitinib, patients with polycythemia vera experienced a significant reduction in hematocrit levels compared with baseline.
Rusfertide Leads to Controlled Hematocrit Levels and Fewer Phlebotomies in Polycythemia Vera
Following treatment with rusfertide, patients with polycythemia vera were able to significantly reduce their need for blood draws.
Newly Approved Pacritinib Continues to Reduce Symptom Burden in Myelofibrosis With Moderate/Severe Thrombocytopenia
Pacritinib helps relieve physical function-related symptoms in adult patients with myelofibrosis and moderate or severe thrombocytopenia.
Orca-T Graft Shows Efficacy, Tolerability in Post-ASCT Myelofibrosis
An expert with Oregon Health & Science University discusses whether Orca-T graft can fulfill an unmet need in the field of allogeneic stem cell transplantation for myelofibrosis.
Ruxolitinib Remains Backbone in Myelofibrosis and MPN Treatment
An expert from Mount Sinai Hospital comments on potential new ruxolitinib combinations to treat patients with myelofibrosis and MPNs.
Ruxolitinib for Polycythemia Vera Not Associated with Increased Secondary Malignancy Risk
Ruxolitinib was not associated with an increased risk of secondary malignancies in patients with polycythemia vera.
Myeloproliferative Neoplasms in Accelerated Phase Continue to Present as Treatment Challenge
Treating patients with myeloproliferative neoplasms in accelerated phase (MPN-AP) remains an ongoing challenge as there are still no standard therapeutic approaches, says an expert.
Allogeneic HSCT Elicits Favorable Outcomes in Myelofibrosis
Allogeneic hematopoietic stem cell transplant (HSCT) is still the sole curative therapeutic modality for patients with myelofibrosis.
Cardiovascular Risk Needs Addressing in Treatment of MPN
Despite relatively good cardiovascular health, a significant percentage of patients with MPN were not prescribed appropriate medication.
Improved OS in Myelofibrosis Associated with Week 24 Transfusion Independence with Momelotinib
The phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials reported that Week 24 transfusion independence resulted in an improved overall survival for patients with myelofibrosis.
Novel Therapies Improve Survival and Symptoms in Myelofibrosis
Novel therapeutics have not only boosted outcomes in myelofibrosis, but paved the way for new combination treatment strategies, too.
New MPN Treatments Improve Survival and Symptom Burden
Combinations of JAK inhibitors and novel agents, such as epigenetic regulators, could help prolong survival in patients with myeloproliferative neoplasms.
JAK Inhibitors Build Momentum in Myelofibrosis Treatment
With additional JAK inhibitors under exploration in the myelofibrosis pipeline, such as momelotinib and pacritinib, FDA-approved options continue to be utilized heavily in the paradigm, explained John O. Mascarenhas, MD.
FDA Approval Sought for Pacritinib to Treat Myelofibrosis With Severe Thrombocytopenia
A rolling submission of a new drug application (NDA) for the JAK2/FLT3 inhibitor pacritinib has been initiated for patients with myelofibrosis and severe thrombocytopenia defined as platelet counts of less than 50,000 μL.
Genetic Testing Improves Treatments, Outcomes in MPNs and MDS
Patients with MDS/MPN unclassifiable, whose genes were found to be the most heterogeneous, had a different molecular landscape that was comparable with those observed within other MDS/MPN.
FDA Approves Fedratinib for Patients With Myelofibrosis
This is the first approval for this patient population in nearly a decade.
FDA Grants Fast Track to Momelotinib to Treat Myelofibrosis
The FDA granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
2 Clarke Drive Cranbury, NJ 08512